Network Pharmacology Uncovers SFI's Anti-Glioma Mechanisms

Study Background and Research Question

Gliomas are among the most aggressive and lethal primary brain tumors, accounting for 30–50% of all such malignancies and presenting formidable therapeutic challenges due to their invasive nature and rapid proliferation. Despite advances in surgery, radiotherapy, and chemotherapy, glioma prognosis remains poor, with median survival for high-grade glioma patients typically less than 17 months. This clinical gap underscores the urgent need for innovative therapeutic strategies, particularly those addressing the molecular mechanisms underlying glioma growth and migration. Shenqi Fuzheng injection (SFI), a traditional Chinese medicine formulation containing Codonopsis pilosula and Astragalus membranaceus, is widely used as an adjuvant to chemotherapy in the clinic. However, the precise molecular pathways through which SFI exerts anti-glioma effects have remained unclear, motivating the current network pharmacology-based investigation (Li et al., 2024).

Key Innovation from the Reference Study

The core innovation of the referenced study lies in its integration of network pharmacology with targeted experimental validation to unravel the molecular mechanism by which SFI inhibits glioma proliferation and migration. By systematically mapping SFI’s bioactive components and their putative targets in the context of glioma biology, the authors identified the SRC/PI3K/AKT signaling pathway as a central node mediating these effects. This work not only clarifies the multi-component, multi-target nature of SFI, but also provides a mechanistic rationale for its observed clinical efficacy as an adjuvant in cancer therapy. The application of network pharmacology—an approach that leverages computational and systems biology tools to predict compound-target-disease interactions—enabled a comprehensive view of the complex pharmacological landscape, moving beyond single-target hypotheses.

Methods and Experimental Design Insights

The study employed a two-pronged approach:

• Network Pharmacology Analysis: The investigators first curated the major bioactive ingredients of SFI (26 in total) and mapped them to 110 molecular targets using public databases. In parallel, 3,343 glioma-associated targets were identified. Cross-referencing revealed 79 shared targets, highlighting potential mechanistic intersections.
• In Vitro and In Vivo Validation: Experimental validation was performed using established human glioma cell lines (U87, T98G) for in vitro assays, and a subcutaneous tumor model in C57BL/6 mice (GL261 cells) for in vivo studies. Functional assays included CCK-8 for proliferation, EdU incorporation, plate cloning, scratch and Transwell migration assays, immunofluorescence, flow cytometry for cell cycle analysis, and Western blotting for pathway interrogation. Tumor tissue was further evaluated by H&E staining and immunohistochemistry.

This workflow enabled a robust connection between computational predictions and biological outcomes (Li et al., 2024).

Core Findings and Why They Matter

Key results from the study include:

• Suppression of Glioma Cell Proliferation: SFI significantly inhibited proliferation and colony formation in U87 and T98G glioma cells, as shown by CCK-8, EdU, and plate cloning assays.
• Cell Cycle Arrest: SFI induced S-phase arrest in glioma cells, reducing the proportion of cells advancing to mitosis.
• Inhibition of Migration and EMT Markers: Migration assays and molecular analyses indicated that SFI downregulated epithelial-mesenchymal transition (EMT) markers, further restraining the invasive capacity of glioma cells.
• In Vivo Tumor Suppression: SFI administration in the GL261 mouse model led to reduced tumor growth and lower expression of proliferation markers in tumor tissue.
• Mechanistic Pathway Elucidation: Western blot and network pharmacology analyses converged on the SRC/PI3K/AKT pathway as a pivotal mediator of SFI’s anti-glioma effects.

These findings provide mechanistic depth to the clinical observation that SFI, as an anti-angiogenic compound, can enhance the efficacy of conventional therapies and suggest that targeting SRC/PI3K/AKT signaling may be a viable strategy for overcoming glioma progression.

Comparison with Existing Internal Articles

Several recent internal articles address related themes, offering complementary perspectives on anti-angiogenic research and VEGF receptor inhibitors. For instance, "Network Pharmacology Reveals SFI's Anti-Glioma Mechanisms" similarly highlights the multi-target actions of SFI and its impacts on tumor angiogenesis. Meanwhile, articles such as "AAL-993: Precision VEGF Receptor Inhibitor for Tumor Angiogenesis" and "AAL-993 in Tumor Angiogenesis: Mechanistic Insights & Translational Impact" focus on the use of selective VEGF receptor inhibitors like AAL-993 in translational models. While SFI primarily modulates the SRC/PI3K/AKT axis with broad multi-component actions, AAL-993 exemplifies a highly selective approach, directly inhibiting VEGFR-1, -2, and -3 tyrosine kinases with nanomolar potency. This contrast underscores the spectrum of anti-angiogenic strategies now available for tumor biology research, from herbal multi-target agents to precision small molecules.

Limitations and Transferability

While the reference study provides compelling evidence for SFI’s anti-glioma effects and the involvement of the SRC/PI3K/AKT pathway, several limitations should be considered:

• Model Systems: The primary cell lines used (U87, T98G, GL261) represent standard glioma models but may not capture the full heterogeneity of patient tumors.
• Complex Botanical Composition: As SFI comprises multiple plant-derived compounds, the precise contribution of individual constituents remains unresolved, which may pose challenges for reproducibility and regulatory translation.
• Mechanistic Breadth: While SRC/PI3K/AKT signaling is implicated, additional pathways—such as those governing angiogenesis (e.g., VEGF)—may be involved but were not directly interrogated in this study.
• Translational Gaps: The findings are robust at the preclinical level but require further validation in diverse models and eventual clinical settings.

Nevertheless, the methodological integration of network pharmacology and experimental validation provides a valuable framework for investigating other anti-angiogenic compounds and signaling inhibitors in tumor models.

Protocol Parameters

• SFI dosing (in vivo): As applied in the referenced study, SFI was administered to GL261 tumor-bearing mice (dosing regimen details are provided in the full text here), typically via intraperitoneal injection.
• Cell culture assays: U87 and T98G cells were treated with SFI for 24–72 hours prior to proliferation and migration analyses.
• Pathway analysis: Western blotting for SRC, PI3K, and AKT phosphorylation was used to assess pathway inhibition following SFI exposure.
• Workflow recommendation: When dissecting angiogenic and proliferative mechanisms in tumor models, consider combining network pharmacology predictions with functional cell-based and animal assays to validate target engagement and phenotypic outcomes.

Research Support Resources

For researchers seeking to model angiogenesis inhibition or investigate the interplay between growth signaling and tumor vascularization, selective VEGF receptor inhibitors provide valuable tools. AAL-993 (SKU C3730) is a potent and selective VEGFR-1, -2, and -3 inhibitor, extensively characterized for in vitro and in vivo anti-angiogenic studies according to the product information. Its robust selectivity profile enables mechanistic studies of tumor angiogenesis and metastasis, complementing broader-acting compounds like SFI. For more detailed protocol examples or mechanistic comparisons, researchers may consult related internal articles on tumor angiogenesis modeling and SFI’s network pharmacology mechanisms.